花生过敏治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

在治疗方案的进步以及意识和诊断不断提高的推动下，2024年至2032年全球花生过敏治疗市场规模的复合年增长率将达到12.1%。口服免疫疗法和新生物製剂等创新为控制花生过敏提供了更有效、更有针对性的解决方案。此外，对这种疾病的认识的提高和诊断技术的改进导致了更高的诊断率和更大的治疗需求。

这些发展确保了早期干预和更好的管理，随着越来越多的人寻求先进且有效的花生过敏治疗方案，扩大了市场。 2024 年 8 月，澳洲推出了一种针对花生过敏婴儿的突破性口服免疫疗法。该计划由国家过敏卓越中心和默多克儿童研究所合作，在 10 家儿科医院推出了标准化护理模式。

这项倡议凸显了人们越来越认识到及时介入和整体护理方法的重要性。此举可能会激励其他国家实施类似的计划，从而扩大花生过敏治疗的全球市场并推动进一步的研究和投资。

花生过敏治疗格局依给药途径、药物类别、配销通路和地理区域进行分类。

到 2032 年，口腔细分市场有望实现显着增长，这要归功于其用户友好的管理方式以及患者对口腔治疗的兴趣不断上升。口服溶液，包括免疫治疗片剂和胶囊，为控制花生过敏提供了一种简单且非侵入性的方法。这些方法有助于逐渐脱敏，并有可能持久缓解过敏反应。随着研究和开发的不断进步，口服疗法的功效不断提高，加上患者的强烈依从性，巩固了其在花生过敏治疗领域的领先地位。

到 2032 年，零售药局凭藉其广泛的影响力和消费者可及性，将巩固其在市场上的主导地位。零售药局提供各种非处方药和处方药解决方案，是应对花生过敏的人的首选。他们能够即时提供药物、针对过敏原的产品和量身定制的咨询服务，从而增强了消费者之间根深蒂固的信任。这种信任与广泛的分销网络相结合，使零售药局处于市场的前沿。

亚太地区预计将在花生过敏治疗市场中占据重要份额，预计到 2032 年复合年增长率将强劲。 。人们对过敏管理的认识不断提高，加上治疗方法的突破，进一步推动了这个趋势。此外，该地区的经济进步转化为医疗保健支出的增加和更广泛的尖端治疗方法。鑑于亚太地区巨大的市场潜力和迅速的进步，它成为全球花生过敏治疗领域的关键参与者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 花生过敏的盛行率不断上升
    • 免疫治疗的批准增加
    • 增加开发新治疗方式的投资
    • 及时治疗花生过敏的意识不断提高
  • 产业陷阱与挑战
    • 免疫治疗费用高昂
    • 初始治疗阶段的安全问题
• 成长潜力分析
• 未来市场趋势
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 可注射
• 口服
• 其他给药途径

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 肾上腺素
• 抗组织胺药
• 免疫疗法
• 其他药物类别

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 其他分销管道

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Adamis Pharmaceuticals Corporation
• AdvaCare Pharma
• Aimmune Therapeutics Inc.
• Amneal Pharmaceuticals LLC
• Amphastar Pharmaceuticals, Inc.
• CVS Pharmacy
• DBV Technologies
• Kaleo
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi
• TerSera Therapeutics LLC
• Teva Pharmaceuticals Industries Ltd.

Global Peanut Allergy Treatment Market size will register a 12.1% CAGR from 2024 to 2032, propelled by advancements in treatment options and growing awareness and diagnosis. Innovations such as oral immunotherapy and new biologics offer more effective and targeted solutions for managing peanut allergies. Also, increased awareness about the condition and improved diagnostic techniques lead to higher diagnosis rates and a greater demand for treatment.

These developments ensure early intervention and better management, expanding the market as more individuals seek advanced and effective treatment options for peanut allergies. In August 2024, Australia unveiled a groundbreaking oral immunotherapy for infants with peanut allergies. This initiative, a collaboration between the National Allergy Centre of Excellence and Murdoch Children's Research Institute, rolled out a standardized care model across 10 pediatric hospitals.

This initiative highlights the increasing acknowledgment of the importance of timely interventions and holistic care approaches. Such a move could motivate other nations to implement comparable programs, thereby broadening the global market for peanut allergy treatments and fueling further research and investments.

The peanut allergy treatment landscape is categorized by route of administration, drug class, distribution channel, and geographical region.

The oral segment is poised for significant growth up to 2032, attributed to its user-friendly administration and the rising patient inclination towards oral therapies. Oral solutions, including immunotherapy tablets and capsules, present a straightforward and non-invasive approach to managing peanut allergies. These methods facilitate gradual desensitization, potentially offering lasting relief from allergic responses. With ongoing advancements in research and development, the heightened efficacy of oral therapies, coupled with strong patient adherence, solidifies their leading role in the peanut allergy treatment arena.

By 2032, retail pharmacies are set to cement their dominance in the market, thanks to their vast reach and consumer accessibility. Offering a diverse array of both over-the-counter and prescription solutions, retail pharmacies stand out as a go-to for those navigating peanut allergies. Their capability to provide instant access to medications, allergen-specific products, and tailored consultations fosters deep-seated trust among consumers. This trust, combined with an expansive distribution network, positions retail pharmacies at the forefront of the market.

Asia Pacific is on track to capture a significant share of the peanut allergy treatment market, with projections indicating a robust CAGR through 2032. This growth is fueled by the region's vast and growing population, a rising incidence of peanut allergies, and an evolving healthcare framework. Heightened awareness regarding allergy management, coupled with breakthroughs in treatment methodologies, further propels this trend. Moreover, the region's economic strides translate to increased healthcare expenditures and broader access to cutting-edge treatments. Given Asia Pacific's immense market potential and swift advancements, it stands as a pivotal player in the global peanut allergy treatment landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of peanut allergies
    • 3.2.1.2 Increasing approvals for immunotherapeutic treatments
    • 3.2.1.3 Increasing investments for developing new treatment modalities
    • 3.2.1.4 Rising awareness towards timely treatment of peanut allergies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of immunotherapeutic treatments
    • 3.2.2.2 Safety issues during initial treatment phase
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Oral
• 5.4 Other routes of administration

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Epinephrine
• 6.3 Antihistamines
• 6.4 Immunotherapies
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Adamis Pharmaceuticals Corporation
• 9.2 AdvaCare Pharma
• 9.3 Aimmune Therapeutics Inc.
• 9.4 Amneal Pharmaceuticals LLC
• 9.5 Amphastar Pharmaceuticals, Inc.
• 9.6 CVS Pharmacy
• 9.7 DBV Technologies
• 9.8 Kaleo
• 9.9 Mylan N.V.
• 9.10 Novartis AG
• 9.11 Pfizer Inc.
• 9.12 Regeneron Pharmaceuticals Inc.
• 9.13 Sanofi
• 9.14 TerSera Therapeutics LLC
• 9.15 Teva Pharmaceuticals Industries Ltd.